Get the Stockscreener App
54.90
3.35%
-1.90
After Hours:
55.55
0.655
+1.19%
Guardant Health Inc stock is traded at $54.90, with a volume of 2.65M.
It is down -3.35% in the last 24 hours and down -0.37% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$56.80
Open:
$55.215
24h Volume:
2.65M
Relative Volume:
1.11
Market Cap:
$6.85B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-12.95
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-8.71%
1M Performance:
-0.37%
6M Performance:
+27.37%
1Y Performance:
+114.60%
1-Day Range:
$53.67
$55.63
1-Week Range:
$53.67
$61.36
52-Week Range:
$20.14
$68.00
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
54.90 | 7.05B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Fred Alger Management LLC Purchases 302,145 Shares of Guardant Health, Inc. $GH - MarketBeat
Adalta Capital Management LLC Sells 4,600 Shares of Guardant Health, Inc. $GH - MarketBeat
Shield Blood Test Yields High Sensitivity, Specificity for CRC Screening in Expansion Cohort of Average-Risk Adults - OncLive
Parkman Healthcare Partners LLC Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
More Blood Tests for Cancer Hit the Market - Barron's
Guardant Health, Inc. $GH Stock Holdings Cut by Temasek Holdings Private Ltd - MarketBeat
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership - Yahoo Finance
Guardant Health, Inc. $GH Holdings Cut by Exome Asset Management LLC - MarketBeat
Guardant Health, Inc. $GH Stock Position Decreased by Cubist Systematic Strategies LLC - MarketBeat
Select Medical, Guardant Health, Artivion, PacBio, and Intuitive Surgical Shares Are Falling, What You Need To Know - Barchart.com
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Cinctive Capital Management LP Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Canada Pension Plan Investment Board Has $3.90 Million Stock Position in Guardant Health, Inc. $GH - MarketBeat
Ieq Capital LLC Takes $660,000 Position in Guardant Health, Inc. $GH - MarketBeat
Eventide Asset Management LLC Reduces Holdings in Guardant Health, Inc. $GH - MarketBeat
Screener Results Flag Guardant Health Inc. as Oversold2025 Pullback Review & Risk Controlled Stock Pick Alerts - beatles.ru
Guardant Health at Morgan Stanley Conference: Innovations in Cancer Diagnostics - Investing.com Canada
Is Guardant Health Inc. a good ESG investmentJuly 2025 Reactions & Weekly Top Performers Watchlists - beatles.ru
Guardant Health partners with PathGroup to expand blood test screening By Investing.com - Investing.com South Africa
Candlestick Reversal Detected on Guardant Health Inc.’s ChartJuly 2025 Chart Watch & Low Drawdown Trading Techniques - beatles.ru
Guardant Health partners with PathGroup to expand blood test screening - Investing.com
What’s the analyst consensus on Guardant Health Inc.Quarterly Portfolio Review & Fast Gain Swing Alerts - beatles.ru
Guardant Health Expands Cancer Test Access with PathGroup Deal - AInvest
Guardant Health’s Strategic Expansion with PathGroup: A Catalyst for Long-Term Growth in Precision Oncology - AInvest
Guardant Health, PathGroup partner to bring Shield blood test to 250+ hospitals across 25 states - MarketScreener
Guardant Health Announces Partnership with PathGroup Bringing Sh - GuruFocus
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States - Yahoo Finance
MPM Bioimpact LLC Sells 10,083 Shares of Guardant Health, Inc. $GH - MarketBeat
The Manufacturers Life Insurance Company Raises Stake in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (NASDAQ:GH) Reaches New 12-Month HighShould You Buy? - MarketBeat
New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening - CancerNetwork
Can Guardant Health Inc. deliver consistent dividendsJuly 2025 Setups & Advanced Swing Trade Entry Alerts - beatles.ru
Live market analysis of Guardant Health Inc.July 2025 Opening Moves & Weekly High Return Stock Forecasts - Newser
Canaccord Genuity Remains a Buy on Guardant Health (GH) - The Globe and Mail
PDT Partners LLC Sells 32,760 Shares of Guardant Health, Inc. $GH - MarketBeat
Is Guardant Health Inc. a turnaround storyEarnings Recap Summary & Weekly Watchlist for Hot Stocks - خودرو بانک
Growth Review: How does Guardant Health Inc. score in quality rankingsJuly 2025 PreEarnings & Fast Gain Stock Trading Tips - خودرو بانک
What to expect from Guardant Health Inc. in the next 30 daysMarket Performance Report & Community Shared Stock Ideas - Newser
Is Guardant Health Inc. showing signs of accumulationBull Run & Free Weekly Watchlist of Top Performers - Newser
Guardant Health’s Shield blood test shows 84% sensitivity for colorectal cancer - Investing.com Canada
Guardant Health reports positive clinical readout update for Shield algorithm - Yahoo Finance
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - biospace.com
Trexquant Investment LP Has $7.69 Million Stake in Guardant Health, Inc. $GH - MarketBeat
Signal strength of Guardant Health Inc. stock in tech scannersJuly 2025 Patterns & Smart Swing Trading Techniques - Newser
Detecting price anomalies in Guardant Health Inc. with AIOptions Play & Real-Time Volume Spike Alerts - Newser
Multi asset correlation models including Guardant Health Inc.2025 Support & Resistance & Safe Swing Trade Setups - Newser
Volume spikes in Guardant Health Inc. stock – what they meanJuly 2025 Sentiment & Community Trade Idea Sharing - Newser
Guardant Health Surges to $280M in Volume as Stock Plunges 5.69% to 378th Rank - AInvest
The Oncology Institute, Inc. shares rise 1.70% intraday after Guardant Health's positive clinical readout update for its Shield™ blood test. - AInvest
Guardant Health shares drop 9% after data release for Shield colorectal cancer screening test. - AInvest
Guardant Health Stock Falls on Colorectal Cancer Test UpdateNews and Statistics - IndexBox
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):